2. Search Result
Search Result
Results for "

lamivudine

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0250
    Lamivudine
    Maximum Cited Publications
    6 Publications Verification

    BCH-189

    		 HIV Reverse Transcriptase HBV Infection Cancer
    Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .
    Lamivudine
  • HY-B0250R
    Lamivudine (Standard)

    BCH-189 (Standard)

    		 HIV Reverse Transcriptase HBV Infection Cancer
    Lamivudine (Standard) is the analytical standard of Lamivudine. This product is intended for research and analytical applications. Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .
    Lamivudine (Standard)
  • HY-119691
    Alamifovir

    LY582563; MCC-478

    		 HBV Infection
    Alamifovir (LY582563; MCC-478), a purine nucleotide analogue proagent, shows potent activity against wild type and lamivudine resistant hepatitis B virus (HBV). Alamifovir has high activity against HBV replication and sustained antiviral effect .
    Alamifovir
  • HY-131603
    Lamivudine triphosphate

    3TCTP

    		 Reverse Transcriptase HCV HBV SARS-CoV Infection
    Lamivudine triphosphate (3TCTP) is a phosphorylated Lamivudine (HY-B0250) (a nucleoside analogue). Lamivudine triphosphate inhibits the Reverse Transcriptase of HIV or HBV viruses to block viral replication by chain termination. Lamivudine triphosphate is also an inhibitor of the RdRp activity of the NS5B subunit of the HCV. Lamivudine triphosphate can be incorporated into the nascent RNA by the SARS-CoV-2 RdRp, thus halting mutations in the nascent SARS-CoV-2 RNA .
    Lamivudine triphosphate
  • HY-B0250A
    Lamivudine salicylate

    BCH-189 salicylate

    		 HIV Reverse Transcriptase HBV Infection Cancer
    Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine salicylate can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .
    Lamivudine salicylate
  • HY-135330
    Lamivudine-13C,15N2

    		HIV Reverse Transcriptase Infection
    Lamivudine- 13C, 15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus .
    Lamivudine-13C,15N2
  • HY-B0250S
    Lamivudine-15N,d2

    BCH-189-15N,d2

    		 HBV HIV Reverse Transcriptase Isotope-Labeled Compounds Infection Cancer
    Lamivudine- 15N,d2 is 15N and deuterated labeled Lamivudine (HY-B0250). Lamivudine (BCH-189) is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus. Lamivudine salicylate can penetrate the CNS .
    Lamivudine-15N,d2
  • HY-W777161
    Lamivudine-15N2,13C

    BCH-189-15N2,13C

    		 Isotope-Labeled Compounds Others
    Lamivudine- 15N2, 13C (BCH-189- 15N2, 13C) is 13C and 15N labeled Lamivudine .
    Lamivudine-15N2,13C
  • HY-B0250S1
    Lamivudine-13C,15N2,d2

    BCH-189-13C,15N2,d2

    		 Isotope-Labeled Compounds HBV Reverse Transcriptase HIV Infection
    Lamivudine-13C,15N2,d2 (BCH-189-13C,15N2,d2) is a 13C, 15N, and deuterium labeled Lamivudine (HY-B0250). Lamivudine is an orally active and blood-brain barrier permeable nucleoside reverse transcriptase inhibitor (NRTI). Lamivudine inhibits HIV reverse transcriptase 1 and 2 and hepatitis B virus (HBV) reverse transcriptase .
    Lamivudine-13C,15N2,d2
  • HY-116252
    (±)-trans-Lamivudine

    		HIV Infection
    (±)-trans-Lamivudine is separated from the salt of (S)-(+) mandelic acid. (±)-trans-Lamivudine forms cocrystals with (S)-BINOL. (±)-trans-Lamivudine is promising for research of human immunodeficiency virus infection .
    (±)-trans-Lamivudine
  • HY-144215
    TLR8 agonist 4

    		HBV Inflammation/Immunology
    TLR8 agonist 4 showed effective inhibition on wild-type and drug-resistant (lamivudine and entecavir) HBV strains. The IC50 values are 0.15 and 0.10 respectively μM.
    TLR8 agonist 4
  • HY-B0255
    Adefovir dipivoxil
    1 Publications Verification

    GS 0840

    		 HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite Infection Cancer
    Adefovir dipivoxil, an adenosine analogue, is an oral proagent of the nucleoside reverse transcriptase inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and HBV Lamivudine-resistant strains . Adefovir dipivoxil shows anti-orthopoxvirus activity.
    Adefovir dipivoxil
  • HY-19447A
    Besifovir Dipivoxil maleate

    LB80380 maleate

    		 HBV Infection
    Besifovir Dipivoxil maleate (LB80380 maleate) is an oral proagent of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies [2]
    Besifovir Dipivoxil maleate
  • HY-B0255R
    Adefovir dipivoxil (Standard)

    		HBV Reverse Transcriptase Orthopoxvirus Endogenous Metabolite Infection Cancer
    Adefovir dipivoxil (Standard) is the analytical standard of Adefovir dipivoxil. This product is intended for research and analytical applications. Adefovir dipivoxil, an adenosine analogue, is an oral proagent of the nucleoside reverse transcriptase inhibitor Adefovir. Adefovir dipivoxil inhibits both the wild type and HBV Lamivudine-resistant strains . Adefovir dipivoxil shows anti-orthopoxvirus activity.
    Adefovir dipivoxil (Standard)
  • HY-116633
    BCM-599

    		Endogenous Metabolite Infection
    BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .
    BCM-599

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: